Immunologic Analysis of Peripheral Blood and Aspirated Thromb In AMI Patients

Immunol Feature in Circulation and Thromb in AMI Patients Clinical Trial

— ATAIA  

Official title:

Immunologic Analysis of Aspired Thromb and Circulatory Immune Cell in AMI Patients

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT02704806
• Other study ID #: Cthromb20160401
• Status: Not yet recruiting
• Phase: N/A
• First received: March 5, 2016
• Last updated: March 9, 2016
• Start date: April 2016
• Est. completion date: April 2018

Study information

• Verified date: March 2016
• Source: Jilin University
• Contact: n/a
• Is FDA regulated: No
• Health authority: China: Food and Drug Administration
• Study type: Observational

Clinical Trial Summary

Researchers use FCM to analyze the immunol cell feature and its corresponding activation status, as well as the thromb aspirated through the thromb aspiration device in AMI patients

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 60
• Est. completion date: April 2018
• Est. primary completion date: April 2017
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 30 Years to 80 Years

Eligibility

Inclusion Criteria:

• uncomplicated AMI patients

Exclusion Criteria:

• any self immune disease and recent (within 1 month) or any chronic infection

Study Design

Observational Model: Case Control, Time Perspective: Prospective

Related Conditions & MeSH terms

• Immunol Feature in Circulation and Thromb in AMI Patients

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Jilin University

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	immunologic feature of AMI patients		1 month	No